2007β肾上腺素能受体阻滞剂用于高血压治疗的中国专家共识


	2007β肾上腺素能受体阻滞剂用于高血压治疗的中国专家共识	★★★

作者：bduxinj 文章来源：中国医师报点击数：更新时间：2008-6-5 10:55:36

　　参考文献：

　　[1] Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 2005, 366:1545-1553.

　　[2] 2006 NICE/BHS guidelines of HYPERTENSION-Management of hypertension in adults in primary care: partial update. P1－94

　　[3] Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of aterial pressure. J Hypertens, 1996, 14(suppl5): 159-165.

　　[4] Julius S, Nesbitt S. Sympathetic overactivity in hypertension: a moving target. Am J Hypertens, 1996, 9: 113s-120s.

　　[5] Mancia G. The sympathetic nervous system in hypertension. J Hypertens, 1997, 15: 1553-1565.

　　[6] MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J, 1985, 291:97-104

　　[7] Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992, 304:405-412.

　　[8] J Wikstrand Primary prevention in patients with hypertension: comments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study. Am Heart J, 1988, 116(1 Pt 2): 338-347.

　　[9] Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre andomized controlled trial. Lancet. 2005, 366:895-906.

上一页 [1] [2] [3] [4] [5] [6] [7] [8] 下一页